SeamlessRep · October 2026
A Decision Many Manufacturers Make Too Early
At some point in every international life science manufacturer’s market development, the same question comes up: when is the right time to replace — or complement — the outsourced sales partner with an in-house sales team?
Most companies make this decision either too early or too late. Too early, because they treat an initial revenue success as a signal to scale immediately. Too late, because they avoid the complexity of a permanent hire even when the market volume would clearly justify its own structure.
This article places both models side by side — with concrete criteria for when each one is the right choice.
What Is a CSO — and How Does It Differ from a Distributor?
CSO stands for Contract Sales Organisation: an external partner who delivers sales services in your name. In the life science context, that means:
- The CSO acquires and manages customers under your brand name
- Customer contracts run directly with you — not with the CSO
- The CSO receives a fee consisting of a fixed retainer and a revenue-based commission
- You retain full visibility into customer contacts, pipeline and pricing
This is fundamentally different from a distributor, who buys your product on their own account and resells it at their own margin — without you knowing who your end customer is.
The In-House Model: When It Makes Sense
Your own sales employee in DACH is the right decision when several conditions are met simultaneously:
1. The market volume justifies the fixed costs. An experienced life science sales manager costs you, including all associated expenses, €150,000–€230,000 in the first year. If your DACH revenue or addressable market potential does not justify this at a realistic pipeline conversion rate, entering the market on your own is too expensive.
2. You have validated market data. You know which customer segments buy, at which price point and with what cycle. This data should come from a real pipeline — not an Excel forecast.
3. You want to scale control over customer knowledge. At some point, customer relationships, technical knowledge and market understanding become so valuable that you want to build and retain them internally.
4. Your product line is complex enough that a full-time specialist is more efficient than a partner serving multiple clients.
The CSO Model: When It Is the Better Choice
Outsourced sales through a CSO partner is the right choice when:
You don’t yet know the DACH market. An established CSO partner brings market knowledge that a new hire takes 12–18 months to build. In the entry phase, that knowledge is worth more than your own person in an office.
You want to minimise fixed-cost risk. A retainer model can be terminated. A permanent employment contract in Germany cannot — at least not without considerable effort.
You need speed. A CSO partner can be active within 4–6 weeks. A recruitment process in DACH realistically takes 4–6 months, with a further 6–12 months of ramp-up.
You want to test before you commit. The CSO model delivers market data, pipeline quality and customer feedback — exactly the foundation you need to later decide whether and how to scale.
The Hybrid: CSO as a Bridge to a Permanent Hire
In practice, the most sensible sequence for most international manufacturers is not “CSO or in-house” — it’s “CSO, then in-house.”
Phase 1 (months 1–18): the CSO partner opens the market, builds pipeline, delivers market data and first closings.
Phase 2 (from month 12–24, depending on market development): the decision to hire your own sales manager is made on the basis of real data. The CSO partner supports the handover, since all customer relationships have belonged to you from the start.
This model avoids the most common mistake: risking an expensive permanent hire in a market you don’t yet know well enough.
Comparison: CSO vs. In-House at a Glance
| Criterion | CSO / Outsourced Sales | In-House Sales Manager |
|---|---|---|
| Time to market | 4–6 weeks | 6–18 months |
| Fixed costs year 1 | well below a full hire (retainer) | €150,000–€230,000 |
| Termination risk | Low (end of contract) | High (German employment law) |
| Market knowledge at start | Available immediately | Must be built up |
| Ownership of customer relationships | 100% with the manufacturer | 100% with the manufacturer |
| Scalability | Limited at very high volume | Good for established business |
| Makes sense from DACH revenue | €0 – €1.5M | From ~€1M validated revenue |
Conclusion: The Sequence Is What Matters
The CSO model and in-house sales are not mutually exclusive — they follow one another. A manufacturer who starts in DACH with a CSO partner makes the permanent hire decision later on the basis of real market data rather than hope.
A manufacturer who starts directly with a permanent hire is betting on a market they don’t yet know — with a candidate whose network they couldn’t verify, with a budget that may or may not give them 18 months of runway.
The sequence is not a compromise. It is the more rational decision.
SeamlessRep supports international life science manufacturers in building a sustainable sales presence in Germany, Austria and Switzerland — as a CSO partner in the entry phase, with handover support when the market justifies its own structure.
Terms on request. You start with a 90-day sprint: a fixed monthly fee and clear milestones, then scale with a monthly retainer plus success commission. You receive a proposal within 48 hours of the alignment call.

Pascal ZimmermannGründer SeamlessRep · 15+ Jahre Life Science im DACH-MarktFounder SeamlessRep · 15+ years in life science sales across DACH